Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
2013
Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of multisystem LCH (MS-LCH), for which optimal therapy has been elusive. Stratified by risk organ involvement (high [RO+] or low [RO–] risk groups), >400 patients were randomized. RO+ patients received 1 to
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
38
References
231
Citations
NaN
KQI